Скачать или смотреть Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME

Pre-dose intraocular pressure (IOP) outcomes were comparable in eyes with diabetic macular edema (DME) receiving intravitreal aflibercept 8 mg or 2 mg, according to a new analysis of the phase 2/3 PHOTON trial.1

In an interview with HCPLive, Mark Barakat, MD, the founder and director of research at Retina Macula Institute of Arizona, indicated the one-year data across the posthoc analysis of PHOTON demonstrated the strong tolerability of aflibercept 8 mg in patients with DME.

“The take-home message here is that the data was spectacularly unimpressive, meaning that there’s nothing to see here,” Barakat told HCPLive. “When you look at eyes treated with the 8 mg dose, with the pre-dose IOP throughout one year’s worth of data, it remained remarkably stable. If you look at the changes, there’s hardly any difference.”

Highlights
0:08 Monitoring IOP in DME
0:59 Post-hoc analysis of PHOTON
1:45 Impact of aflibercept 8 mg on IOP outcomes
3:18 Safety profile of aflibercept 8 mg

Link to full story: https://www.hcplive.com/view/mark-bar...
More ARVO coverage: https://www.hcplive.com/conference/arvo

#ophthalmology #conference #retina